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nemia as a Risk Factor and
herapeutic Target in Heart Failure
. Michael Felker, MD,* Kirkwood F. Adams, JR, MD, FACC,† Wendy A. Gattis, PHARMD,*
hristopher M. O’Connor, MD, FACC*
urham and Chapel Hill, North Carolina
Anemia has recently been recognized as an important comorbid condition and potentially
novel therapeutic target in patients with heart failure (HF). Anemia is common in HF
patients, with a prevalence ranging from 4% to 55% depending on the population studied.
Multiple potential mechanisms of interaction exist between anemia and the clinical syndrome
of HF, including hemodilution, inflammatory activation, renal insufficiency, and malnutri-
tion. A growing body of literature from observational databases and clinical trials suggests that
anemia is an independent risk factor for adverse outcomes in patients with HF. Although
preliminary data suggest that treatment of anemia may result in significant symptomatic
improvement in HF, aggressive treatment of anemia may also be associated with increased
risk of hypertension or thrombosis. Multiple ongoing studies will provide definitive data on
the balance of risks and benefits of anemia treatment in chronic HF. (J Am Coll Cardiol
2004;44:959–66) © 2004 by the American College of Cardiology Foundationt
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(“There are, in truth, no specialties in medicine, since to
know fully many of the most important diseases a man must
be familiar with their manifestations in many organs.”
—William Osler, The Army Surgeon,
Medical News, Philadelphia, 64:318, 1894.
Chronic heart failure (HF) is a rapidly growing public
ealth problem. Despite the significant successes of phar-
acologic blockade of neurohormonal activation in HF, the
egative or neutral results of multiple recent trials suggest
hat we have reached a “ceiling of benefit” with regard to
his approach (1). This has led to the search for novel
echanisms by which to address the persistent morbidity
nd mortality associated with HF. Anemia has recently been
emonstrated to be a common comorbid condition in
atients with HF, and multiple observational studies have
emonstrated an independent association between lower
emoglobin (Hb) and adverse clinical outcomes in this
yndrome. Although these findings have generated substan-
ial interest in anemia as a potentially important therapeutic
arget in patients with HF, current HF guidelines provide
o specific recommendations for evaluation or treatment of
nemia (2,3). The purpose of this review is to outline the
urrent understanding of the association between anemia
nd HF and assess the existing and emerging data on
nemia as a potential treatment target, including the poten-
From the *Duke Clinical Research Institute, Durham, North Carolina; and
University of North Carolina-Chapel Hill, Chapel Hill, North Carolina. Dr. Felker
s the site principal investigator for the Study of Anemia in a Heart Failure Population
STAMINA-HFP) registry, a heart failure registry sponsored by Amgen. Dr. Adams
as acted as principal investigator for the STAMINA-HFP registry and other clinical
tudies sponsored by Amgen. Additionally, Dr. Adams has performed consulting/
dvisory board activities and been on a speaker’s bureau for Amgen. Dr. O’Connor has
erformed consulting/advisory board activities for Amgen.
Manuscript received March 24, 2004; revised manuscript received April 18, 2004,Pccepted May 19, 2004.ial benefits and risks of treating anemia in the setting of
F.
EARCH STRATEGY AND SELECTION CRITERIA
search of published literature was performed using the
EDLINE database using the following search terms:
nemia, hemoglobin, heart failure, oxygen delivery, cardio-
yopathy, and erythropoietin. Studies were included if they
valuated the role of Hb concentration in the pathophysi-
logy or outcomes of patients with HF. Reference lists from
dentified studies were also reviewed to identify other
otentially relevant references. Given the rapidly evolving
iterature in this area, abstracts from recent scientific meet-
ngs were also reviewed for potentially relevant studies that
ave not yet been published.
COPE OF THE PROBLEM
ublished estimates of the prevalence of anemia in patients
ith HF vary widely, with ranges from 4% to 55% (4–10).
easons for this wide variation include differences in the HF
opulation studied, in study methods, and in the definition
f anemia used. Although the most commonly accepted
efinition of anemia is that of the World Health Organi-
ation (Hb13 g/dl in men or12 g/dl in women), studies
ave varied considerably in the criteria used to classify
atients as anemic. In general, the prevalence of anemia is
reater in less-selected populations (such as claims data) and
ower in highly selected populations such as patients en-
olled in clinical trials. Anemia appears to be more common
n patients with more severe disease, with a reported
revalence in patients with New York Heart Association
NYHA) functional class IV populations as high as 79% (6).
atients hospitalized with HF have significantly higher rates
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Anemia in Heart Failure September 1, 2004:959–66f anemia than outpatient populations. The prevalence of
nemia in selected HF studies is shown in Table 1.
TIOLOGY AND PATHOPHYSIOLOGY OF ANEMIA IN HF
lthough anemia is common in HF, it remains controver-
ial whether its high prevalence in HF patients is directly
elated to HF itself or is primarily due to other comorbid
onditions. Heart failure is a disease of the elderly, a
opulation where the prevalence of anemia is high irrespec-
ive of cardiac status (11). Multiple comorbid conditions are
ommon in HF patients, in particular renal insufficiency,
hich is closely associated with the development of anemia
12,13). Although many studies have identified a high
revalence of anemia in patients with HF (Table 1), few
ave carefully examined the relationship between the bur-
en of comorbidity and the prevalence of anemia. Hussein
t al. (14) recently presented data on the attributable cause
f anemia from a retrospective cohort study of 699 consec-
tive outpatient visits to a HF clinic. An explanation for
nemia other than heart failure was identified in 98% of the
tudy patients, with the most common etiologies being renal
nsufficiency (defined as creatinine clearance 60 ml/min/
2) and iron, folate, or B12 deficiency. Although limited by
ts retrospective design, this study suggests that mechanisms
ther than HF may be responsible for anemia in a signifi-
ant proportion of HF patients. A prospective ongoing
tudy including both specialty and community sites, the
tudy of Anemia in a Heart Failure Population
STAMINA-HFP) registry, is evaluating the prevalence,
tiologies, and mechanisms of anemia in a broad population
f HF patients (15).
Although the causal relationship between HF and anemia
emains poorly defined, there are multiple potential mech-
nisms by which the HF syndrome could contribute to the
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ESRD  end-stage renal disease
Hb  hemoglobin
HF  heart failure
NYHA  New York Heart Association
rHuEPO  recombinant human erythropoietin
TNF  tumor necrosis factor
able 1. Prevalence of Anemia in Selected HF Studies
Study Population
l-Ahmad et al. (4) LV dysfunction / symptoms, clinical tr
anner et al. (7) Tertiary care HF clinic
zekowitz et al. (8) New HF diagnosis, claims data
ozaffarian et al. (5) Severe chronic HF, clinical trial
orwich et al. (9) Heart transplant referrals single-center
osiborod et al. (10) Medicare patients, claims data
elker et al. (38) Acute decompensated HF, clinical trial
ilverberg et al. (6) Chronic HF, single-center trialb  hemoglobin; Hct  hematocrit; HF  heart failure; LV  left ventricular.evelopment of anemia. These include hemodilution, renal
ysfunction, proinflammatory cytokines, malnutrition due
o right-sided HF, decreased perfusion to the bone marrow,
nd drug therapy (such as angiotensin-converting enzyme
ACE] inhibitors). In reality, it is likely that several of these
echanisms are active simultaneously, and that anemia in
F is the result of a complex interaction between cardiac
erformance, neurohormonal and inflammatory activation,
enal function, and bone marrow responsiveness. This
nterplay has been termed the “cardio-renal-anemia syn-
rome” (16). A conceptual model for these interactions is
hown in Figure 1.
Expansion of plasma volume is a characteristic of the HF
yndrome, and, therefore, some anemia may be dilutional
ather than due to a true decrease in red blood cell mass
17). In a recently published study of 37 HF patients by
ndrone et al. (18), true anemia (i.e., a decrease in red blood
ell mass) was present in 54%, and hemodilution was
resent in 46%. Notably, in this study both hemodilution
nd true anemia were associated with adverse survival, with
he worst survival seen in patients with hemodilution.
Renal insufficiency is common in HF, with a prevalence
rom 30% to 50% depending on the definition used and
n Definition of Anemia Prevalence
6,563 Hct  35% 4%
193 Hb  12 15%
12,065 MD defined (ICD9 codes) 17%
1,130 Hct  37.6% 20%
1,061 Hb  13 men, 12 women 30%
2,281 Hct  37% 48%
949 Hb  13 men, 12 women 49%
142 Hb  12 55%
igure 1. A conceptual model of mechanisms involved in the interaction
etween heart failure, renal function, bone marrow, and anemia. ACE 
ngiotensin-converting enzyme; EPO  erythropoietin; LVH  left ventric-
lar hypertrophy; RAS  renin-angiotensin system; RBC  red blood cell;
NF  tumor necrosis factor.ial
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September 1, 2004:959–66 Anemia in Heart Failureopulation studied (12,19). In patients with advanced renal
isease, progressive renal dysfunction leads to a decrease in
irculating levels or erythropoietin, with a subsequent de-
rease in bone marrow erythrocyte production and Hb
evels. It is well-established that anemia in patients with
nd-stage renal disease (ESRD) is associated with a variety
f adverse cardiac consequences, including the development
f left ventricular hypertrophy, left ventricular dilation, and
rank clinical HF (20,21). As shown in Figure 1, there is a
omplex interaction between renal insufficiency, erythropoi-
tin production, and HF. Indeed, despite the high preva-
ence of renal dysfunction, circulating levels of erythropoi-
tin are generally normal-to-elevated in HF, with a
orrelation between the degree of erythropoietin elevation
nd worsening functional class (17). Increased renal produc-
ion of erythropoietin may be driven by worsening cardiac
erformance and subsequent renal hypoperfusion and hyp-
xia, which is a powerful stimulus for erythropoietin pro-
uction. In light of this elevation of erythropoietin levels in
dvanced HF, the high prevalence of anemia in this popu-
ation is particularly notable. Anemia in HF may be a state
f relative resistance to the effects of erythropoietin, with
ersistent anemia despite high normal or frankly elevated
rythropoietin levels. Several potential explanations for
rythropoietin resistance in HF have been proposed, includ-
ng the influence of proinflammatory cytokines and malnu-
rition.
Chronic HF is known to be a state of persistent inflam-
atory activation, and higher levels of circulating proin-
ammatory cytokines are known to be associated with
reater disease severity and worsened clinical outcomes
22–24). Proinflammatory cytokines such as tumor necrosis
actor (TNF)-alpha and interleukin-6 also have direct ef-
ects on the bone marrow, and are implicated in the
echanism of anemia of chronic disease (25). Elevated
evels of circulating proinflammatory cytokines lead to
ecreased erythropoietin production and resistance to the
ffects of erythropoietin on bone marrow production of red
lood cells. Given that both proinflammatory cytokine
ctivation and anemia are more pronounced in patients with
ore severe HF, it is attractive to hypothesize that inflam-
atory activation is a major contributor to anemia in this
opulation. Recently presented data confirm the association
etween elevation of circulating inflammatory markers and
able 2. Association of Anemia and Outcomes in Selected HF S
Study Population
l-Ahmad et al. (4) LV dysfunction  symptoms, clinical trial
zekowitz et al. (8) New HF diagnosis, claims data
orwich et al. (9) Heart transplant referrals, single-center
osiborod et al. (10) Medicare patients, claims data
ozaffarian et al. (5) Severe HF, clinical trial
elker et al. (38) Acute HF, clinical trial
bbreviations as in Table 1.nemia, with patients with anemia and HF demonstrating fignificantly higher levels of TNF-alpha and TNF soluble
eceptors 1 and 2 (26).
Other potential mechanisms may involve regulation of
rythropoietin secretion from the kidney, either from the
F syndrome itself or from pharmacologic treatment.
utonomic dysfunction, which is known to be present in
F, may result in impaired renal production of erythropoi-
tin even in the setting of significant stimuli for erythrocyte
roduction (27,28). Therapy with ACE inhibitors is a
ainstay of HF therapy, with clearly documented improve-
ents in long-term survival (29–31). Some data have
uggested, however, that ACE inhibitor therapy may reduce
b concentration in patients with HF. Therapeutic doses of
CE inhibitors have been shown to decrease renal secretion
f erythropoietin in patients with hypertension (32), renal
nsufficiency (33), polycythemia (34), and chronic HF (35).
he mechanistic role these considerations may play in the
evelopment of anemia in patients with HF is not clear.
NEMIA AND OUTCOMES
variety of observational studies have found lower Hb or
ematocrit to be associated with adverse clinical out-
omes in HF (Table 2). This relationship persists
hether considering Hb concentration as a continuous
ariable or anemia as a categorical variable. Anemia has
een shown to be a risk factor for new cardiovascular
vents in the general population (36). Data from the
ramingham study found that lower hematocrit was a
ignificant risk factor for the development of symptom-
tic HF (37). Data from a large single-center cohort of
atients with primarily NHYA functional class IV symp-
oms referred for cardiac transplantation identified an
ssociation between lower Hb and impaired hemodynam-
cs, lower functional capacity, and decreased long-term
urvival (9). These findings persisted when patients were
ubdivided into a variety of subgroups based on gender,
F etiology, and age. Notably, this study identified a
ubstantially increased risk even in patients with relatively
ild anemia (Hb 12.6 g/dl for men and Hb 11.6 g/dl
or women). In the Outcomes of a Prospective Trial of
ntravenous Milrinone for Exacerbations of Chronic
eart Failure (OPTIME-CHF) study of patients hospi-
alized with decompensated HF, Hb levels were also
s
Outcome
Adjusted Hazard/
Odds Ratio Unit Change
ortality 1.027 1% Hct
ortality 1.34 Anemic vs. not
ortality 1.13 1 g/dl Hb
ortality 1.02 1% Hct
ortality 1.03 1% Hct
eath or rehospitalization 1.12 1 g/dl Hbtudie
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Anemia in Heart Failure September 1, 2004:959–66omes, with a 12% increased risk of death or rehospital-
zation at 60 days for every decrease of 1 g/dl of Hb (38).
nemia also contributes to the exercise intolerance that is
major morbidity in chronic HF. A recently published
tudy in 93 men with HF found that Hb was a significant
ndependent predictor of maximal exercise tolerance as
easured by peak oxygen consumption, even after con-
rolling for ejection fraction, age, and renal function (39).
ot all studies have supported the association of anemia
nd adverse outcomes in HF. A study by Kalra et al. (40)
f 552 patients with new-onset HF found a significant
ncidence of anemia in this cohort (18% with Hb 11.5
/dl) but no association between baseline Hb and survival
fter adjustment for other variables. The authors con-
luded that anemia early in the disease course was likely
ue to factors other than HF and therefore, was unlikely
o be associated with prognosis.
When taken as a whole, the observational data appear
o suggest a relationship between anemia and outcomes
n patients with HF. However, such studies must be
nterpreted with caution due to their retrospective design,
nd should not be construed as demonstrating a caus-
tive, mechanistic link between anemia, HF, and out-
omes. Whether such a link exists is not clear from the
urrently available data. Multiple theoretical reasons have
een postulated to explain the observed association be-
ween anemia and outcomes in patients with HF. The
resence of anemia may simply be a marker for greater
everity of HF or greater burden of comorbidity. A
ecently presented study using data from the National
eart Failure Project found that, while lower hematocrit
evels were associated with higher mortality, this associ-
tion was related to a greater severity of illness and
urden of comorbidity, and that hematocrit was not
ndependently associated with one-year mortality (41).
Patients with anemia are more likely to have concomitant
enal insufficiency, which has been shown to be a powerful
redictor of worsened outcomes in HF (12,19). Multiple
tudies, however, have demonstrated an independent effect
f anemia even after controlling for renal function (4,8–10),
uggesting that lower Hb is not simply a surrogate for renal
isease. Patients with greater severity of HF may have more
olume retention and, therefore, more anemia due to
emodilution. Horwich et al. (9), however, reported that
b was a predictor of adverse outcome even after adjust-
ent for volume overload as measured by invasive hemo-
ynamic monitoring. Alternatively, anemia may contribute
irectly to the pathophysiologic state in HF. Anemia results
n decreased oxygen carrying capacity, which may be com-
ensated for in the normal heart by increasing heart rate and
troke volume, resulting in an increase in cardiac output and
aintenance of tissue oxygen delivery (42). These adaptive
esponses may be limited, however, in patients with coro-
ary artery disease or HF (43). Subsequent myocardial or
issue hypoxia may result in increased sympathetic activity, ieurohormonal activation, and cytokine release, leading to a
icious cycle of HF progression.
NTERVENTIONAL STUDIES
he consistent association of anemia with adverse clinical
utcomes in HF has led to substantial interest in anemia as
potential therapeutic target. Potential treatments for
nemia include the use of red blood cell transfusions and
reatment with erythropoietin analogs to increase red blood
ell production. The impact of red blood cell transfusion on
ardiovascular disease is controversial. Although a “transfu-
ion threshold” of maintaining the hematocrit 30% in
atients with cardiovascular disease has been commonly
ccepted, this concept has been based primarily on expert
pinion rather than on clinical trials (44). In addition to the
otential risk of infectious transmission, concerns have been
aised about the potential immunosuppressive effects of
lood transfusion (45). A randomized controlled trial of a
estrictive (7 g/dl) versus liberal (10 g/dl) transfusion strat-
gy in critically ill patients (26% of whom had cardiovascular
isease) reported no significant difference in 30-day mor-
ality, although there was a trend towards reduced mortality
n the restrictive transfusion arm (46). In contrast, a retro-
pective review of Medicare claims data in elderly patients
ith acute myocardial infarction found that transfusion in
atients with admission hematocrit 0.30 was associated
ith improved 30-day mortality rates (47). Given the risks
nd costs of red blood cell transfusion and its uncertain
enefit, it does not appear that transfusion represents a
iable therapeutic strategy for the routine treatment of
nemia in HF.
Recombinant human erythropoietin (rHuEPO) has be-
ome a mainstay in the treatment of anemia in patients with
SRD. In addition to well-documented improvements in
uality-of-life and survival, data from patients with ESRD
ave suggested that rHuEPO treatment leads to an im-
rovement in a variety of measures of cardiac performance,
ncluding reduced left ventricular hypertrophy and improved
jection fraction and cardiac output (48–50). Three small
tudies have been published directly examining the effect of
HuEPO therapy on clinical outcomes in patients with
eart failure. In an uncontrolled study, Silverberg et al. (6)
emonstrated an improvement in ejection fraction, NYHA
unctional class, and hospitalization after treatment with
rythropoietin and intravenous iron in a group of 26 patients
ith NYHA functional class III to IV HF. In this study, the
ose of rHuEPO was adjusted to maintain an Hb level of 12
/dl. The same group subsequently conducted a small
andomized trial of rHuEPO and intravenous iron in 32
atients with NYHA functional class III to IV HF, which
emonstrated that treatment of anemia in this patient
opulation resulted in improved functional class and a
ecrease in the need for hospitalization (51). Several fea-
ures of these studies suggest the need for caution in the
nterpretation of these results. Both studies examined very
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September 1, 2004:959–66 Anemia in Heart Failuremall numbers of patients. The initial study was not
andomized and had no control group. Additionally, the
andomized trial was significantly limited by its lack of a
lacebo control and the fact that neither patients nor
nvestigators were blinded to treatment assignment. Given
he subjectivity of assessments of functional class and in
riteria for diuretic dosing or HF hospitalization, these end
oints must be interpreted very cautiously in the setting of
n unblinded study.
A recent randomized, single-blind, placebo-controlled
tudy by Mancini et al. (52) evaluated the effect of 3 months
f erythropoietin treatment on exercise capacity in 26
atients with anemia and NYHA functional class III to IV
F. This study demonstrated significant improvements in
eak oxygen consumption (VO2 max) with erythropoietin
reatment (from 11  0.8 to 12.7  2.8 in the rHuEPO-
reated patients [p  0.05] vs. no significant change in the
ontrol patients). A significant correlation was observed
etween elevations in Hb with rHuEPO treatment and
ncreased VO2. Notably, the improvement in exercise per-
ormance with rHuEPO treatment was observed whether
he anemia was found to be from decreased red blood cell
ass or from hemodilution. Although this study was
andomized, placebo-controlled, single-blinded, and had an
bjective end point (VO2 max), the small sample size
uggests the need for larger confirmatory studies before
hese results can be widely accepted.
All three of these studies used rHuEPO in a regimen
imilar to the one used in patients with ESRD. Newer
rythropoietin analogs have been developed (such as darbe-
oetin alfa) that have a longer half-life and require less
requent administration, potentially making them more
ttractive for HF therapy. An ongoing phase II study of
arbepoetin in patients with HF and anemia will provide
mportant preliminary data on the potential efficacy of this
gent in the HF population.
Another area of ongoing investigation deals with direct
ffects of rHuEPO on the heart. Erythropoietin receptors
re present in a variety of tissues, including the heart, and
rythropoietin appears to have anti-inflammatory and anti-
poptotic properties (53). Recently published studies have
emonstrated that treatment with rHuEPO favorably at-
enuated ischemia-reperfusion injury in a mouse model
54,55). Whether these findings will have physiologic rele-
ance in humans remains unknown, but they do suggest an
dditional potential mechanism for beneficial effects of
rythropoietin treatment in human HF.
OTENTIAL RISKS OF ANEMIA TREATMENT
s with all therapies, potential benefits must be balanced
gainst potential risk (primum non nocere), and concern does
xist about possible adverse effects of anemia correction in HF.
n large part, these concerns are based on the results of a large
andomized trial, the Normal Hematocrit Treatment trial, that
emonstrated a non-significant increase in mortality in hemo- oialysis patients with clinical heart disease (heart failure or
schemic heart disease) who were treated with erythropoietin to
goal hematocrit of 42% as opposed to 30% (56). This trial
as terminated prematurely when the Data Safety Monitoring
ommittee concluded that the trial would be unable to reach
ts prestated end point of demonstrating improved outcomes in
he higher hematocrit group. Although not statistically signif-
cant, the relative risk of death or non-fatal myocardial infarc-
ion in the high hematocrit group was 1.3 (95% confidence
nterval, 0.9 to 1.9). Paradoxically, however, higher hematocrit
alues in this study were associated with a decreased mortality
ate within each study group, suggesting that the higher
ematocrit per se was not responsible for the increased mor-
ality. These issues have led to significant controversy in
nterpreting these results (57). Other smaller studies have not
eplicated the results of the Normal Hematocrit Treatment
rial. Data from the Canadian Multicenter study in 146
atients with asymptomatic left ventricular hypertrophy or left
entricular dilation found no evidence of improvement in
chocardiographic parameters but did show improvements in
uality-of-life with normalization of Hb (target, 13.5 g/dl)
58). There was no difference in rates of thrombosis between
he two groups, but there was a greater need for antihyperten-
ive therapy in the high Hb group. The Spanish Cooperative
uality of Life study group performed an uncontrolled trial in
SRD patients without HF, and found that normalization of
ematocrit was associated with improved quality of life and
unctional status (59).
Several mechanisms could theoretically result in harmful
ffects from increasing Hb in HF patients. Erythropoietin
herapy is associated with worsening hypertension in 20% to
0% of patients on hemodialysis (60). Additionally, eryth-
opoietin use may be associated with increased risk of
hrombosis, especially of vascular access grafts (61–64).
hese effects may be due to an increase in platelet activa-
ion, increased blood viscosity, or effects on the levels of
roteins C and S (65–67). Finally, erythropoietin therapy
ay be associated with endothelial activation and the release
f endothelin, a circulating peptide that has been shown to
e associated with adverse outcomes in HF (68,69). A
ummary of the potential risks and benefits of erythropoi-
tin therapy in HF is shown in Table 3.
Given the potential risks associated with erythropoietin
herapy, caution seems well-justified until more definitive data
able 3. Potential Benefits and Risks of Treating Anemia in
eart Failure
Potential Benefits Potential Risks
mproved oxygen delivery Increased thrombosis
mproved exercise tolerance Platelet activation
ttenuate adverse remodeling Hypertension
ntiapoptotic Endothelial activation
Improved QOL
Decrease in hospitalizations
Improved survival
OL  quality of life.n the potential clinical benefits of anemia therapy in HF
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Anemia in Heart Failure September 1, 2004:959–66re available. Many important questions remain unanswered,
ncluding the optimal Hb target and appropriate rate of rise of
b. Importantly, the ultimate benefit of a therapy is related to
he relative balance of risks and benefits in a given patient
opulation. Thrombolytic therapy, for example, carries a finite
isk of intracranial hemorrhage, but this risk is outweighed by
he clinical benefits in appropriately selected patients with
cute ST-segment elevation myocardial infarction. Such a
alance of risks and benefits can only be established in
ppropriately designed, randomized, controlled trials. Such
tudies, several of which are ongoing, will provide substantially
reater understanding of balance of risks and benefits of
harmacologic treatment of anemia in patients with HF.
URRENT RECOMMENDATIONS/FUTURE DIRECTIONS
t present there is insufficient data to make a general
ecommendation for aggressive treatment of anemia in
atients with HF. A diagnostic evaluation for potentially
eversible causes of anemia (such as iron deficiency or occult
lood loss) and subsequent treatment, if identified, is
ppropriate in all patients. Although pilot data on the
reatment of anemic HF patients with erythropoietin ana-
ogs are promising, the studies published thus far have been
ignificantly limited by very small sample size, lack of
linding, and the use of subjective end points. Treatment of
ild anemia with erythropoietin analogs can, thus, not be
onsidered a proven therapy for HF based on currently
vailable data, and the results of larger, more carefully
ontrolled clinical trials will be required before such treat-
ent could be considered a viable therapy. The history of
rug development in HF is notable for many therapies that
ppeared promising in small, early studies (such as chronic
notropic therapy or TNF-alpha blockade) only to be proven
eutral or harmful when evaluated in large, carefully con-
rolled trials (70,71). Such experience must serve as a
autionary tale and, therefore, it is crucial that appropriate
aution be exercised until data from prospective, blinded,
ontrolled trials of adequate size are available. Many such
tudies are currently being planned or are underway, includ-
ng prospective studies addressing the prevalence and inci-
ence of anemia in HF populations (15), the mechanisms of
nemia in HF, and the effect of anemia treatment on quality
f life, exercise tolerance, morbidity, mortality, and costs.
iven the history of drug development in HF, a mixture of
ptimism and caution would appear to be the appropriate
ttitude towards anemia therapy in HF at present.
ONCLUSIONS
nemia is increasingly recognized as an important comor-
id condition in patients with HF. Although the exact
echanism is not well-defined, it appears that anemia in
F patients is the result of a complex interaction of cardiac
erformance, renal homeostasis, bone marrow responsive-
ess, and concomitant drug therapy. Multiple observational
tudies have confirmed the substantial prevalence of anemian a variety of HF populations. Observational data has also
uggested a significant independent association of lower Hb
evels with adverse clinical outcomes. Although preliminary
nd limited, several pilot studies have demonstrated the
otential for therapies targeted at anemia to impact clinical
utcomes in HF. Given the potential risks of worsening
ypertension and thrombosis, larger, carefully controlled
tudies will be required before such therapy can be accepted.
uch studies must also address important questions about
echanisms and the cost-benefit of this type of therapy.
iven the therapeutic ceiling that seems to have been
eached with current modalities of neurohormonal modu-
ation, anemia may represent an important novel target for
ddressing the substantial morbidity and mortality associ-
ted with the ongoing HF epidemic.
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